Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adavosertib + fludarabine + cytarabine + filgrastim
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous, Intrathecal
01
Overview
This combination therapy consists of the Wee1 kinase inhibitor adavosertib (AZD1775) and the FLAG chemotherapy regimen, which includes fludarabine, cytarabine, and filgrastim. Adavosertib works by inhibiting the WEE1 G2 checkpoint kinase, a key regulator of the G2/M cell cycle checkpoint. By inhibiting WEE1, the drug prevents cancer cells from repairing DNA damage before entering mitosis, thereby sensitizing them to DNA-damaging agents. Fludarabine and cytarabine are antimetabolites that interfere with DNA synthesis and repair, while filgrastim (G-CSF) is a hematopoietic growth factor used to stimulate white blood cell production and potentially prime leukemia cells for chemotherapy. This combination is primarily being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML), particularly in pediatric and young adult populations.
- Other names
- AZD1775 + FLAGadavosertib + FLAGAZD1775 + fludarabine + cytarabine + filgrastim
02
Targets
DNADNA polymerase familyCSF3R (Granulocyte colony-stimulating factor receptor)RNR (Ribonucleotide reductase)WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on adavosertib + fludarabine + cytarabine + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adavosertib + fludarabine + cytarabine + filgrastim.